SCHEMBL31247467

SCHEMBL31247467

CSCc1cccnc1Nc1cc(N)ncn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 6/20 0.43
▸ JAK2 O60674 2/20 0.40
▸ TYK2 P29597 2/20 0.40
▸ CDK1 P06493 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCNA2 P20248 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ CDK5 Q00535 1/20 0.37
▸ CDK5R1 Q15078 1/20 0.37
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36
▸ SCN9A Q15858 1/20 0.35
▸ EGFR P00533 3/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ ASIC3 Q9UHC3 1/20 0.34
▸ HTT P42858 1/20 0.33
▸ NOD2 Q9HC29 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31247639 0.82 GRM5 (0.62) GRM5ASIC3HTT
SCHEMBL31247523 0.81 GRM5 (0.58) GRM5JAK2TYK2CDK1CCNB1
SCHEMBL31247372 0.72 CDK1 (0.46) JAK2TYK2CDK1CCNB1CCNA2
SCHEMBL31300245 0.72 CDK1 (0.46) JAK2TYK2CDK1CCNB1CCNA2
SCHEMBL31247403 0.70 SYK (0.42) JAK2TYK2CDK1CCNB1CCNA2
SCHEMBL28963294 0.68 CDK5 (0.45) JAK2TYK2CDK1CCNB1CCNA2
SCHEMBL29920007 0.68 CDK5 (0.45) JAK2TYK2CDK1CCNB1CCNA2
SCHEMBL31247628 0.68 JAK2 (0.38) GRM5JAK2TYK2CDK1CCNB1
SCHEMBL3431925 0.67 CDK1 (0.60) CDK1CCNB1CCNA2CCNE1CDK2
SCHEMBL6871017 0.65 MAOA (0.58) JAK2EGFRCYP1A2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 — — EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 — — US disclosed
US-20240425484-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-26 — — US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 GRM5 1437/4885JAK2 16/4885TYK2 1/4885
US-20240425484-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 GRM5 2396/4885JAK2 3/4885TYK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback